Small molecules that target messenger RNA have therapeutic potential, but the field still lacks an unqualified success. Companies differ on how to move the resurgent field forward.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Childs-Disney, J. L. et al. Nat. Rev. Drug Discov. 21, 736–762 (2022).
Ratni, H., Scalco, R. S. & Stephan, A. H. ACS Med. Chem. Lett. 12, 874–877 (2021).
Bhattacharyya, A. et al. Nat. Commun. 12, 7299 (2021).
Rzuczek, S. G. et al. Nat. Chem. Biol. 13, 188–193 (2017).
Bush, J. A. et al. Proc. Natl Acad. Sci. USA 119, e2210532119 (2022).
Chen, J. L. et al. J. Am. Chem. Soc. 142, 8706–8727 (2020).
Warner, K. D., Hajdin, C. E. & Weeks, K. M. Nat. Rev. Drug Discov. 17, 547–558 (2018).
Zhang, P. et al. Proc. Natl Acad. Sci. USA 117, 1457–1467 (2020).
Townshend, R. J. L. et al. Science 373, 1047–1051 (2021).
Costales, M. G. et al. Proc. Natl Acad. Sci. USA 117, 2406–2411 (2020).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Garber, K. Drugging RNA. Nat Biotechnol 41, 745–749 (2023). https://doi.org/10.1038/s41587-023-01790-z
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41587-023-01790-z
